Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial

Sulkowski MS, Hézode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with HCV GT1 mono-infection and HIV/HCV coinfection (C-WORTHY): a randomised, open-label phase 2 trial. Vierling JM, Mallolas J, Pol S, Kugelmas M, Murillo A, Weis N, et al. Lancet. 2015;285(9973):1087-1097.

Publication Type:

Journal Article

Authors:

M S Sulkowski; Christophe Hézode; Gerstoft, J.; et, al

Source:

Lancet, Volume 285, Issue 9973, p.1087-1097 (2015)

Cited On:

External Third-party Web Link:

https://www.ncbi.nlm.nih.gov/pubmed/25467560

Export Citation:
RIS Format
Top